REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda (REBOA-PPH)
Primary Purpose
Post-partum Hemorrhage
Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
REBOA, Resuscitative Endovascular Occlusion of the Aorta
National guidelines
Sponsored by
About this trial
This is an interventional treatment trial for Post-partum Hemorrhage focused on measuring REBOA, Resuscitative Endovascular Occlusion of the Aorta
Eligibility Criteria
Inclusion Criteria:
- Patients with life-threatening PPH (PPH and a systolic blood pressure equal to or less than 80 mmHg)
- Oral consent
Exclusion Criteria:
- Prior cardiac arrest
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
REBOA
National guidelines
Arm Description
Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)
Treatment according to Uganda national guidelines for post-partum hemorrhage.
Outcomes
Primary Outcome Measures
Adverse outcome
The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy
Secondary Outcome Measures
Adverse outcome excluding 'inevitable' hysterectomies
The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids
Number of AEs and SAEs
Safety of REBOA assessed by AEs and SAEs
Maternal death
The proportion of participants with a maternal death
Emergency hysterectomy
The proportion of participants with emergency hysterectomy
Acute kidney injury
The proportion of participants with acute kidney injury
Transfusions
The number of blood transfusion units
Hemoglobin
Post-partum hemoglobin concentration after 1, 2, 3 and 42 days
Full Information
NCT ID
NCT05598502
First Posted
October 25, 2022
Last Updated
July 4, 2023
Sponsor
Centre For International Health
Collaborators
Makerere University, Kawempe National Referral Hospital, St. Olavs Hospital, Helse Stavanger HF, University of Liverpool, University of Padova
1. Study Identification
Unique Protocol Identification Number
NCT05598502
Brief Title
REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda
Acronym
REBOA-PPH
Official Title
Phase III, Open-label, Randomized Clinical Trial to Evaluate Efficacy and Safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in Life-threatening Postpartum Haemorrhage in Reducing Adverse Maternal Outcome in Uganda
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 15, 2023 (Anticipated)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre For International Health
Collaborators
Makerere University, Kawempe National Referral Hospital, St. Olavs Hospital, Helse Stavanger HF, University of Liverpool, University of Padova
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background
Maternal mortality rates in many low-income countries (LMICs) remain high. The most prominent cause is bleeding after birth, called postpartum hemorrhage (PPH). In a recent report from Uganda, bleeding is the cause of 42% of all maternal deaths in Uganda.
Large parts of the monitoring of mothers during active management of third stage of labor is aiming to prevent and early detect PPH and take relevant actions. In spite of this and sometimes in referring mothers to tertiary hospitals, mothers will end up in a challenging condition where quick action is needed. A new method has proven successful for such instances, the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). This is a procedure commonly used for trauma of the lower part of the body but rarely used for PPH. In this trial, it is done by an anesthesiologist where a balloon catheter is inserted via the femoral artery in the groin into the aorta and then being inflated. This will prevent blood from passing to the lower part of the body, including the uterus. It will stop the bleeding and allow for the obstetrician to take relevant action. This is a safe procedure for up to 1 hour of inflation.
Objective
To assess the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda.
Study design, setting and population
A phase III, open label, 1:1 randomized clinical trial will be conducted at Kawempe National Referral Hospital, Kampala, Uganda, to evaluate the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care. The inclusion criteria are: a) women with life-threatening PPH and a systolic blood pressure equal to or less than 80 mmHg, b) oral consent. The exclusion criterion is prior cardiac arrest.
The sample size of the trial will be 210 participants. Enrolment will follow a group sequential design approach with two interim analyses at 1/3 and 2/3 of the total sample size, and a final analysis with full sample size.
Utility of the study
It is crucial to explore alternative modalities that could prevent adverse maternal outcomes in life-threatening postpartum hemorrhage in Uganda and the rest of the world.
Detailed Description
Background
Maternal mortality rates in many low-income countries (LMICs) remain high. The most prominent cause is bleeding after birth, called postpartum hemorrhage (PPH). In a recent report from Uganda, bleeding is the cause of 42% of all maternal deaths in Uganda.
Large parts of the monitoring of mothers during active management of third stage of labor is aiming to prevent and early detect PPH and take relevant actions. In spite of this and sometimes in referring mothers to tertiary hospitals, mothers will end up in a challenging condition where quick action is needed. A new method has proven successful for such instances, the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). This is a procedure commonly used for trauma of the lower part of the body but rarely used for PPH. In this trial, it is done by an anesthesiologist where a balloon catheter is inserted via the femoral artery in the groin into the aorta and then being inflated. This will prevent blood from passing to the lower part of the body, including the uterus. It will stop the bleeding and allow for the obstetrician to take relevant action. This is a safe procedure for up to 1 hour of inflation.
Objective
To assess the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda.
General objective
To assess the efficacy and safety of the use of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda.
Specific objective
- To assess if the proportion of either maternal death and/or emergency hysterectomy, can be decreased from 50 % in the control arm (using standard of care alone) to 30 % or less in the intervention arm (using REBOA).
Secondary objectives
To assess if the proportion of either maternal death and/or emergency hysterectomy is lower in the intervention arm when excluding 'inevitable' hysterectomies due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids.
To assess the safety of REBOA in a national referral hospital in a low-income country like Uganda.
To assess if the proportion of maternal deaths is lower in the intervention arm compared to the control arm.
To assess if the proportion of emergency hysterectomy is lower in the intervention arm compared to the control arm.
To assess if the proportion of women with acute kidney injury is lower in the intervention arm compared to the control arm
To assess if the number of blood transfusion units is lower in the intervention arm compared to the control arm.
To assess if post-partum hemoglobin concentration is higher in in the intervention arm compared to the control arm.
To assess the time to insert the REBOA.
Study design, setting and population
A parallel group, open-label, individually 1:1 randomized phase III clinical trial will be conducted at Kawempe National Referral Hospital, Kampala, Uganda, to evaluate the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care.
The sample size of the trial will be 210 participants. Enrolment will follow a group sequential design approach with two interim analyses at 1/3 and 2/3 of the total sample size, and a final analysis with full sample size.
Results from Norway indicate that REBOA could be an efficient way to prevent post-partum hemorrhage ending in an adverse outcome such as death or emergency hysterectomy. It is not clear whether these results can be reproduced in a low-income setting where PPH is more prevalent, and resources are scarce. The REBOA device could reduce the risk of adverse outcome such as death or emergency hysterectomy. It will be compared to standard of care.
Utility of the study
It is crucial to explore alternative modalities that could prevent adverse maternal outcomes in life-threatening postpartum hemorrhage in Uganda and the rest of the world.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-partum Hemorrhage
Keywords
REBOA, Resuscitative Endovascular Occlusion of the Aorta
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Individual randomization
Masking
None (Open Label)
Masking Description
The study statistician will be masked.
Allocation
Randomized
Enrollment
212 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
REBOA
Arm Type
Experimental
Arm Description
Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)
Arm Title
National guidelines
Arm Type
Active Comparator
Arm Description
Treatment according to Uganda national guidelines for post-partum hemorrhage.
Intervention Type
Device
Intervention Name(s)
REBOA, Resuscitative Endovascular Occlusion of the Aorta
Intervention Description
The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
Intervention Type
Other
Intervention Name(s)
National guidelines
Intervention Description
Standard management of postpartum hemorrhage according to Uganda national guidelines
Primary Outcome Measure Information:
Title
Adverse outcome
Description
The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy
Time Frame
42 days
Secondary Outcome Measure Information:
Title
Adverse outcome excluding 'inevitable' hysterectomies
Description
The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids
Time Frame
42 days
Title
Number of AEs and SAEs
Description
Safety of REBOA assessed by AEs and SAEs
Time Frame
42 days
Title
Maternal death
Description
The proportion of participants with a maternal death
Time Frame
42 days
Title
Emergency hysterectomy
Description
The proportion of participants with emergency hysterectomy
Time Frame
42 days
Title
Acute kidney injury
Description
The proportion of participants with acute kidney injury
Time Frame
42 days
Title
Transfusions
Description
The number of blood transfusion units
Time Frame
42 days
Title
Hemoglobin
Description
Post-partum hemoglobin concentration after 1, 2, 3 and 42 days
Time Frame
42 days
Other Pre-specified Outcome Measures:
Title
REBOA insertion time
Description
Time to insert the REBOA
Time Frame
1 day
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with life-threatening PPH (PPH and a systolic blood pressure equal to or less than 80 mmHg)
Oral consent
Exclusion Criteria:
Prior cardiac arrest
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thorkild Tylleskar, MD, PhD
Phone
004748074410
Email
thorkild.tylleskar@uib.no
First Name & Middle Initial & Last Name or Official Title & Degree
Josaphat Byamugisha, MD, PhD
Phone
00256772580330
Email
jbyamugisha@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thorkild Tylleskar, MD, PhD
Organizational Affiliation
University of Bergen, Norway
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28355242
Citation
Stensaeth KH, Sovik E, Haig IN, Skomedal E, Jorgensen A. Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage. PLoS One. 2017 Mar 29;12(3):e0174520. doi: 10.1371/journal.pone.0174520. eCollection 2017.
Results Reference
background
Learn more about this trial
REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda
We'll reach out to this number within 24 hrs